The study investigating the pre-clinical therapeutic potential of apabetalone (RVX-208) in pulmonary arterial hypertension was recently published: "Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension."

A commentary article titled "BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling" was published in the same journal. Here is the pdf link, but if that doesn't work here are another couple of links.

https://www.ncbi.nlm.nih.gov/pubmed/31112388

https://www.atsjournals.org/doi/abs/10.1164/rccm.201904-0877ED